ZNF12

Across TCGA pan-cancer cohorts, ZNF12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF12 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF12 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ZNF12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.151	0.750	.002	21	view →
LUAD	DFS	Median	II,III,IV	0.292	0.793	.038	3	view →
LSCC	DFS	Quartile	III,IV	0.969	0.329	.038	2	view →
HNSC	OS	Median	All	1.000	0.921	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF12–PDAC (DFS)

Open the PDAC breakdown →